Wellcome Sanger Institute Genetic Map Identifies Five Bacterial Capsule Types Causing 70 Percent of Europe's Drug Resistant E. Coli

Sanger Institute researchers identify 90 E. coli capsule types, revealing the "armor" responsible for 70% of multidrug-resistant infections in Europe.

By: AXL Media

Published: Mar 26, 2026, 10:41 AM EDT

Source: Information for this report was sourced from Wellcome Trust Sanger Institute

Mapping the Molecular Shields of Pathogenic Bacteria

A major international research effort led by the Wellcome Sanger Institute and the University of Oslo has produced the first comprehensive genetic atlas of the protective capsules that shield E. coli. By analyzing more than 18,000 bacterial genomes from every continent, the team identified the specific "armor" types that allow the bacteria to evade the human immune system. According to the study published in Nature Microbiology, researchers discovered that E. coli possesses 90 different varieties of these protective shields, nearly two-thirds of which were entirely unknown to science until now. This digital database offers a vital roadmap for scientists attempting to find new ways to penetrate these bacterial defenses.

The Prevalence of Multidrug Resistant Strains in Europe

The investigation revealed that a remarkably small number of capsule types are responsible for the vast majority of severe infections in high-resource settings. In Europe, just five specific capsule types, designated as K1, K5, K52, K2, and K100, account for 70 percent of all multidrug-resistant E. coli bloodstream infections. According to the research data, these same capsules are also heavily involved in urinary tract infections across the UK, Norway, and France. Identifying these specific genetic markers allows healthcare providers to recognize the most dangerous lineages of E. coli, which often transition from harmless residents of the gut to lethal invaders of the blood.

Geographic Diversity in Bacterial Armor

One of the most significant findings of the study is the stark difference between the bacterial strains found in industrialized nations compared to low and middle-income countries. While a handful of capsule types dominate infections in Europe, researchers found much greater diversity in the strains causing serious illness in regions such as Malawi and Pakistan. Dr. Rebecca Gladstone, the study’s first author, noted that this geographic variation is a critical factor for vaccine development. A vaccine designed for the European market might be ineffective in other parts of the world because the bacterial "antigens" or markers being targeted are fundamentally different depending on where a patient lives.